#WhatsYourPlan campaign results in 20 commitments to implement National Dementia Plans
Following the launch of the #WhatsYourPlan campaign in November 2021, ADI examines the campaign’s successes in its first year.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
ADI members in the Caribbean call for urgent action on dementia
Alzheimer and dementia associations in the Caribbean are calling for National Dementia Plans to be created and implemented through the #WhatsYourPlan campaign.
ADI attends Western Pacific policy roundtable discussion
The discussions focused on developing a regional policy brief for the promotion, protection and restoration of mental health in older adults, with the inclusion of a focus on dementia awareness and risk reduction.
Italian national dementia plan to receive funding for first time
Though Italy's National Dementia Plan was first approved in 2014, this is the first time that the plan will receive funding by the Italian government.
ADI’s 34th international and 1st virtual conference opens
ADI 2020 will take place from Thursday, 10 December until Saturday, 12 December and feature over 1,500 delegates from around the world.
Welcome to our new website
We have a new website, with updated design and content. The site works better on mobile devices and brings together our resources, member information and programmes so they are easy to find.
‘Dementia, lessons learned from Qatar’ launched at WISH 2020 Qatar Summit
A new policy briefing, co-authored by ADI, thoroughly examines dementia care policy in Qatar.
New Alzheimer’s disease data platform launched
A new data platform AD Workbench was launched by the Alzheimer’s Disease Data Initiative (ADDI).
Souvenaid results offer hope for those with early Alzheimer’s disease, including Mild Cognitive Impairment
Promising results from a clinical trial have been published in the peer-reviewed journal of the Alzheimer’s Association.
Evidence considered at FDA Advisory Committee for potential first new Alzheimer’s disease treatment in decades
The US Food and Drug Administration has reviewed clinical trial data for Biogen’s drug aducanumab, which aims to treat cognitive and functional decline in Alzheimer’s disease.